Abstract-With more patients taking multiple medications and the increasing digital availability of diagnostic data such as treatment notes and x-ray images, the importance of decision support systems to help dentists in their treatment planning cannot be over emphasised. Based on the hypothesis that a higher similarity ratio between drugs in a drug-pair indicates that the combination of the drug-pair has a higher chance of an adverse interaction, this paper describes an efficient approach in extracting feature vectors from the drugs in a drug-pair to compute the similarity ratio between them. The feature vectors are obtained through a network model where the information of the drugs are represented as nodes and the relationships between them represented as edges. Experimental evaluation of our model yielded a superior F score of 74%.
I. INTRODUCTION
The amount of data available to dentists has increased tremendously in recent years. This has led to increasing dependence on a clinical decision support system (CDSS) to aid the treatment planning process especially for drug prescription. Drugs such as painkillers and antibiotics are very commonly prescribed in the dental setting to relieve pain and resolve infections, in primary and supplementary roles. Reducing and relieving pain with analgesic medications are naturally important procedures within the clinical work-flow of a dental clinic [7] . For patients with an abscessed tooth, common drugs such as amoxicillin and clindamycin are also used to treat the infections as a supplement to a root canal treatment or removing the tooth. Antibiotics are also used after surgical procedures such as placement of dental implants and gum treatment [10] .
Though there are systems which examine the interactions within a pair of drugs, they are not associated with the medical profile of the patient. Hence, we aim to pursue a framework which obtains content-specific data from publicly available data sources, performs data-mining on the data and presents the results to the dentist with consideration of the individual patient's drug allergies and the drugs they are currently taking. Although the data-mining layer of our three-tier framework can include many approaches for extracting information, this paper examines the use of a network model which is based on the hypothesis that a higher similarity ratio indicates a greater chance of an adverse interaction between drugs in a drug-pair. The network model provides an effective platform for obtaining feature vectors and hence their similarity ratio based on the number of common paths connecting the set of common interacting drugs between the drug-pair. In our model, we represent all drugs as nodes in a network to enable us to compute their proximity in terms of the number of shared entities between the drug-pair as reflected in the number of connecting paths between them. The primary theoretical contribution of this research is the use of the network model in hierarchically representing the drug-pairs within the context of a CDSS considering the individual patient's medical profile. Examining the paths linking the common drugs within the set of interacting drugs for each drug in the drug-pair allows the system to arrive at a similarity ratio. This then allows the dentist to decide if the drug is safe for the patient. Such a system containing information on interacting drug-pairs based on the patient's personal profile will also be useful in clinical education relating to drug dispensing, such as in medicine, nursing and pharmacy.
The rest of paper is organised as follows: Section II discusses the related work in data-mining and detection of interactive drug-pairs; Section III explains the framework and Section IV describes the experiment while the results are discussed in V. Section VI describes a clinical scenario to demonstrate if a drug is safe based on a specific patient's profile and Section VII presents the conclusions obtained with an outline of potential future work.
II. RELATED WORK
Many works on drug interactions have been performed in recent years, notwithstanding the lack of a single dataset with information on drug interactions from all publicly available sources [1] . Hence, knowledge representation as per the source of the dataset is used in the design of many CDSS for making diagnostic inferences ( [6] , [5] )
By using data-mining techniques, semantic meanings and context-specific knowledge based on medical profiles of patients can be obtained from the knowledge base. Wright et al. used a data-mining method to identify relationships between diabetic medications [12] . By identifying patterns within the drug database, the system was able to predict the subsequent medication to be prescribed with significant accuracy.
When predicting the relationship of a drug-pair, relevant information from knowledge bases are usually extracted and examined. For example, Tari et al. developed a method combining text mining and automated reasoning to predict enzyme-specific drug-drug interactions (DDI) [11] . Yan et al. also used text mining techniques to create features based on relevant information such as genes and disease names extracted from drug databases to augment limited domain knowledge [13] . These features were then used to build a logistic regression model to predict DDI.
Though these systems predict the extent of drug interaction within the drug-pair, they are not customised to the medical profile of the patient. Of the many methods used to create feature vectors to compute the similarity of a drug-pair to predict DDI, this paper will explore the use of a network model, where drugs are represented on each node with their relationship represented as edges. This model fits into the data-mining layer of our framework as elaborated in the next section.
III. FRAMEWORK
As mentioned earlier, knowledge representation is a typical technique used in CDSS development. The knowledge base needs to be updated regularly to represent knowledge in a timely manner, which is imperative for CDSS user acceptance [3] . The separation of the knowledge base from the main information systems allows the former to be updated and managed effectively, for each layer to be developed and maintained independently while simultaneously ensuring standardised interfacing between layers and cheaper integration with existing systems [4] . Hence our framework has a three-tier architecture ( Figure  1 ) which separates the knowledge layer containing the knowledge base from the data-mining layer and the presentation layer.
The network model, residing in the data-mining layer aims to compute the similarity ratio of a drug-pair based on the feature vectors gathered from the knowledge layer. Our approach adapts from [2] which describes the theoretical foundations of measuring similarity within a network.
To obtain the feature vectors and the similarity ratio within this model, the logarithm begins by formally defining the set of interactive drugs as A r = {a 1 , a 2 ...a k } where r is the attribute of the relationship with the vertex drug-pair, which can be minor, moderate or major.
The items in A is also the subset of out-neighbours of drug
r } This is followed by getting the path and the vectors Get Path Using notation from [9] , the path from drug d 1 to set of interactive drugs A with ratings r is denoted by:
is found in A r at position u, then the u th column in matrix M r will be updated as r, M r (1, u) ←− r.
IV. EXPERIMENT
We chose an experimental approach to assess the accuracy and efficiency of the proposed method, testing the hypothesis that similar drug-pairs have a higher similarity ratio compared to that of dissimilar pairs.
The comprehensive dataset on DDI required for this project was sourced from drugbank.ca, a richly annotated database popularly used to build drug repositories on drug indications [8] .
From the set of drugs that interacts adversely with each drug in the drug-pair, paths and feature vectors were built. This data-mining process aimed to discover the number of common paths for each drug-pair. As explained in Section III, vectors were then built so that a similarity ratio can be computed for the drug-pair.
With the similarity ratio results from the experiment, a threshold of θ = 0.5 was used to predict if the drug-pair was similar. A value of 0.5 or higher meant the drug-pair was considered similar, and a value lower than 0.5 meant the drug-pair was considered dissimilar. The performance of the model was measured by counting the number of correct predictions (true positives). For convenience and ease of computation, the standard metrics recall, precision and F score were used to gauge how well the prediction was being made. Precision indicated how accurately the model predicted drug-pairs as similar, while recall indicated how accurately similar drug-pairs were predicted. Thus,
where T P is True Positive, F N is False Negative, and F P False Positive. Table I: F score distribution   Table I shows the F score when the experiment is run with a dataset of positive pairs and negative pairs. When the threshold is 0.5, the model produces a F score of 0.74 with a recall rate of 0.61 and precision of 0.94. r=1 indicates only common paths in the direct neighbourhood of the drug is considered. When the distance is extended at r=2, where paths connecting the drugs that interact with the drug-pair are also considered, it can be noticed that the F score drops drastically. As expected, the performance deteriorated when additional attributes of adverse interactions were introduced such as minor and moderate interactions. However, due to fewer possible paths when only major interactions were considered, the cut-off occurs sooner, where beyond that, there were no true positives obtained in the experiment. This explains the unavailability of F score when the threshold was over 0.6.
V. RESULTS AND DISCUSSION
Since both positive and negative outcomes are important within the clinical workflow, we also examined the performance of our model to predict true negatives. To do so, a plot of true positive rate tpr against true negative rate tnr (Equation 2) was used to obtain the area under the receiver operating characteristic curve (AUC).
With this plot, at r=1 with paths connecting only the major interactions considered, the AUC yielded 0.61 compared to 0.36 when minor and moderate interactions were included. This was expected due to the noise introduced by the additional paths.
VI. ADAPTING THE MODEL TO PRESCRIPTION SUPPORT FOR DENTAL CLINICS
Our three-tier framework can be easily applied to a clinical environment to support the prescription of drugs to patients. This section describes a typical CDSS to help decide if the drug is safe for prescription.
Given the set of prescription drugs, an algorithm can be developed to adapt the framework to a clinical scenario to ensure the drug is not in adverse relationship with what the patient is taking and is dissimilar to the drugs that the patient is allergic to.
From Algorithm 1, there are two tests that consider the adverse relationship and the similarity within drug-pairs. To facilitate suggestion of an alternative drug by the system, a set of candidate drugs, similar to the drug to be prescribed, was created. Based on the relationship within drug-pairs in the drug taxonomy located in the knowledge layer, the system searched for any adverse relationship between the drug to be prescribed and each drug that the patient is currently taking. If there was no adverse relationship detected, the system proceeded to test for similarity between the drug to be prescribed and each drug in the set of drugs that the patient is allergic to. Each drug in the prescription set of drugs had to clear both tests. If either test was not cleared, an alternative drug in the candidate set was suggested. If the candidate set was exhausted, the system would then be unable to recommend an alternative drug.
Consider a patient who is allergic to penicillin and is currently taking warfarin. During a dental appointment, it is decided that antibiotics are required. The dentist may consider the commonly prescribed amoxicillin. Use of our model will note the similarity of amoxicillin to penicillin, which the patient is allergic to, and will thus recommend an alternative drug. As indicated in Algorithm 1, not only should this drug be dissimilar to penicillin, it should also not be in adverse relationship with warfarin. One such drug that fits both criteria is troleandomycin. On receiving the suggestion of this alternative drug, the dentist can then decide whether it is appropriate to be prescribed after further consideration of the duration and dosage of the patient's current medications.
VII. CONCLUSION
This paper presents the use of a network model in the data-mining of bio-medical data within a three-tier framework, allowing easy updating of the knowledge base and effective presentation of results to the user. Experimental results show that this model performs better when only nodes within the direct neighbourhood of the drug-pair are used to find the common paths within the network. Besides the network model, we plan to compare and contrast this approach with the word embedding approach, where feature vectors are based on the nearest terms to the drug-pair. Not only will this study aid implementation of a personalised CDSS to benefit dentists in the prescription of drugs at point-of-care, our work will also provide potential for more efficient algorithms with the use of a network model in information retrieval, similarity search and machine learning.
